BioCentury | Feb 1, 2016
Emerging Company Profile

Degradation by Degronimid

...Number of employees: Not disclosed Funds raised: $73 million Investors: Cobro Ventures, The Kraft Group, EG Capital...
BioCentury | Jan 11, 2016
Finance

Dollars for degradation

...of C4. Cobro led the round, with participation from Cormorant Asset Management, The Kraft Group, EG Capital...
BioCentury | Jan 11, 2016
Financial News

C4 Therapeutics completes venture financing

...Type: Venture financing Raised: $73 million Investors: Cobro Ventures; Cormorant Asset Management; The Kraft Group; EG Capital...
BioCentury | Jan 8, 2016
Financial News

C4 debuts with $73M, Roche deal

...platform while Dana-Farber was developing it. Other investors included Cormorant Asset Management, The Kraft Group, EG Capital...
BioCentury | May 4, 2007
Financial News

Progen planning financings

...5.9 million PGL shares at A$5.74 in a rights issue underwritten by Bell Potter and eG Capital...
Items per page:
1 - 5 of 5
BioCentury | Feb 1, 2016
Emerging Company Profile

Degradation by Degronimid

...Number of employees: Not disclosed Funds raised: $73 million Investors: Cobro Ventures, The Kraft Group, EG Capital...
BioCentury | Jan 11, 2016
Finance

Dollars for degradation

...of C4. Cobro led the round, with participation from Cormorant Asset Management, The Kraft Group, EG Capital...
BioCentury | Jan 11, 2016
Financial News

C4 Therapeutics completes venture financing

...Type: Venture financing Raised: $73 million Investors: Cobro Ventures; Cormorant Asset Management; The Kraft Group; EG Capital...
BioCentury | Jan 8, 2016
Financial News

C4 debuts with $73M, Roche deal

...platform while Dana-Farber was developing it. Other investors included Cormorant Asset Management, The Kraft Group, EG Capital...
BioCentury | May 4, 2007
Financial News

Progen planning financings

...5.9 million PGL shares at A$5.74 in a rights issue underwritten by Bell Potter and eG Capital...
Items per page:
1 - 5 of 5